RESUMO
Objective: The study investigated the gut content and recorded morphometric and hematological parameters in the Eurasian collared dove (Streptopelia decaocto). Materials and Methods: 24 samples of healthy birds (12 from each sex) were collected from different wetlands in Punjab, Pakistan, from December 2022 until February 2023. Birds were captured live for blood samples, morphometric, and gut analyses. Results: The current study revealed that mensural measurements showed no significant differences in all parameters except tail length, which was significantly longer in males (14.59 ± 0.30) compared to females (12.88 ± 0.43). Hematological parameters were hemoglobin, 23.95 gm/dl; red blood cells, 3.97 × 106/µl; white blood cells, 429.9.67 × 103/µl; hematocrit, 72.14%; mean corpuscular volume, 183.24 FL; mean corpuscular hemoglobin, 61.70 pg; mean corpuscular hemoglobin concentration, 32.37 pg; platelets, 7.01/µl; and red cell distribution width, 110.86/µl. The percentages of neutrophils, lymphocytes, monocytes, and eosinophils were 71.33%, 23.03%, 3.30%, and 1.43%, respectively. The gut content of the Eurasian collared dove mainly consisted of rice, wheat, corn, and millet seeds. Some stony materials were also present. Conclusion: Our study concluded that male and female Eurasian collared doves are alike in biometrics (except tail length) and hematological profiles. Gut content and weight were also similar. Males were slightly larger than females. The gut content showed that the Eurasian collared dove mainly feeds on rice, wheat, corn, and millet seeds. In this study, hematological parameters were also studied.
RESUMO
BACKGROUND: Many human immunodeficiency virus (HIV) infected patients suffer from depr-ession, but a little focus is given to detecting and treating depression in primary health care. Detection of depression can be improved by introducing short, reliable, and valid screening instruments. AIM: To determine the psychometric properties of the patient health questionnaire-2 (PHQ-2) and patient health questionnaire-9 (PHQ-9) for depression screening and diagnosis, and the sensitivity and specificity of the PHQ-2 in HIV infected patients. METHODS: A cross-sectional study was conducted on 158 HIV-infected patients aged 18 years and above in Lahore, Pakistan. PHQ-2 was implemented to screen depression. PHQ-9 was implemented to diagnose major depressive disorder as a reference standard. Reliability, Validity tests and receiver operating characteristic curve were computed. RESULTS: The Cronbach's alpha of PHQ-2 and PHQ-9 were 0.732 and 0.759, respectively. The study results showed that the score of 2 on PHQ-2 indicates the highest Youden's index of 0.924, with both sensitivity and specificity of 0.96, and the area under the curve for PHQ-2 was 0.98 (95%CI: 0.953-0.998). CONCLUSION: Good psychometric properties for the PHQ-2 and PHQ-9 indicated their significant potential as tools for depression screening and diagnosis in the HIV-infected population.
RESUMO
Background: Adverse effects on the health and well-being changes may also express as a decreased sleep quality in COVID-19 patients. This study aimed to assess sleep quality among confirmed COVID-19 patients and the non-COVID-19 Pakistani population. Methods: An online cross-sectional survey was conducted between April and September 2020 in Punjab province, Pakistan. Information about demographic characteristics, COVID-19 diseased status, prior knowledge about COVID-19, and sleep quality using the Pittsburgh Sleep Quality Index (PSQI) was collected. Results: A total of 597 participants were included in this study, 296 (49.6%) COVID-19 patients and 301(50.4%) non-COVID-19 population. The PQSI was used to measure seven distinct sleep components; subjective quality, latency, duration, efficiency, disturbances, medication, and daytime dysfunction. Where mean ± standard deviation (SD) were 0.96 ± 0.743, 1.47 ± 1.032, 0.97 ± 1.006, 0.61 ± 0.995, 1.13 ± 0.649, 0.23 ± 0.651, 1.02 ± 0.861 respectively in total population (N = 597). Sleep latency, sleep duration, and sleep efficiency did not show a significant difference in the T-Test. While sleep quality, sleep disturbances, sleep medication, and daytime dysfunction showed a significant difference between both populations. Conclusion: In conclusion, we highlighted the poor sleep quality in COVID-19 patients as compared to the non-COVID-19 population.
RESUMO
BACKGROUND: Remdesivir is a monophosphoramidate prodrug of an adenosine analog, and it has a broad-spectrum antiviral activity against paramyxoviruses, flaviviruses, and coronaviruses. Remdesivir is associated with decreased hospital stay and improved outcomes in coronavirus- disease 2019 (COVID-19). METHODOLOGY: Of 846 suspected COVID-19 patients admitted to the hospital, 612 SARS-CoV-2 nasopharyngeal RT-PCR positive patients were evaluated for enrollment in this prospective cohort study. 159 RT-PCR positive patients were given remdesivir. Their clinical, biochemical parameters, hospital stay, and outcomes related to morbidity and mortality were followed. RESULTS: Out of the 159 patients, 141 recovered after remdesivir use. The Chi-square test for independence examined the relation between the day of the first dose, dose of remdesivir, and clinical outcome. The standardized case fatality ratio (CFR) in the 453 hospitalized patients who did not receive remdesivir was 32.89% (N = 149) as compared to 11.32% (N = 18) in the patients who received remdesivir. These findings are in keeping with the therapeutic value of remdesivir in symptomatic SARS-CoV-2 infection of varying severity. CONCLUSION: The use of remdesivir is associated with a decrease in the severity of the SARS-CoV-2 infection. Its use is also associated with a decreased length of hospital stay and lower mortality than the patients who did not receive remdesivir.
